國(guó)際新聞精選周三（2017年2月8日）

2017年2月9日 | Filed under: | Posted by: 編輯 D

GW Pharma’s cannabis-derived combo med helps brain cancer patients

After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.

In the phase 2 study, the U.K. biopharma’s cannabidiol (CBD) and tetrahydrocannabinol (THC) candidate, both of which are active ingredients derived from cannabis, showed positive top-line results from an exploratory placebo-controlled trial in 21 patients with recurrent glioblastoma multiforme, or GBM, a particularly aggressive brain tumor that has a poor prognosis.【閱讀全文】

Serono spinout raises €29M for phase 2 Parkinson’s trials

Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials. The Series B positions the Merck Serono spinout to build on last year’s phase 1 success by testing the mGluR4 positive allosteric modulator in larger efficacy studies.【閱讀全文】

Biotechnology Executives Oppose Trump Immigration Policy

Nearly 100 founders and leaders of biotechnology companies have signed a letter rebuking President Donald Trump for the immigration restrictions he put in place through an executive order on January 27. The letter is being published by Nature Biotech, a top scientific journal.

The letter expresses "deep concern and opposition" to Trump's executive order barring the entry of citizens from seven countries. The letter notes that one study showed that 52% of the 69,000 biomedical researchers in the United States were foreign-born. And then it goes further, warning that the policy could deeply damage U.S. leadership in the development of new medicines.【閱讀全文】

美中藥源原創(chuàng)文章，轉(zhuǎn)載注明出處并添加超鏈接，商業(yè)用途需經(jīng)書面授權(quán)。
★更多深度解析訪問(wèn)《美中藥源》~

★ 請(qǐng)關(guān)注《美中藥源》微信公眾號(hào) ★